This application constitutes the fifth competitive renewal of The Mount Sinai School of Medicine Alzheimer's Disease Research Center. We have used the strengths of our well established center to address the new vision of the NIA Center program. We have proposed standardized assessment to be used at all our sites and the EITC will assist us with developing procedures manual, training materials and certification methods to insure that the evaluations can be reliably collected from a range of research staff. The newly established Data Management Core has been intimately involved in the development of the data collection instruments to insure that they can be readily entered into the data warehouse, that clinical and neuropathological information can be acct and integrated and that the extraction of the NACC data set can be accomplished seamlessly. This submission highlights our long standing accomplishments in clinical evaluation and neuropathological characterization of healthy elderly, mild cognitive impairment and early AD. In Project one we will integrate clinical and neuropathological to trace the earliest indicators of cognitive change in aging and dementia I n Projects 2 and 3, leading notions of potential etiologic mechanisms are explored in depth. In this renewal the following Cores and Projects are proposed: ? ? Administrative Core A (M. Sano) ? ? Clinical Research Support Core/ Elmhurst Satellite (D. Marin) ? ? Data Management Core C (V. Haroutunian) ? ? Neuropathology Core D (D. Perl) ? ? Education and Information Transfer Core E (M. Sano/M. Sewell) ? ? Project #1: Selective Neuronal Pathology in the Development of Dementia (P. Hof) ? ? Project #2: Identification and characterization of first messengers that regulate APP processing (J. Buxbaum) ? ? Project #3: PSI Regulates Cleavage and Function of EphrinB ligand and EphB Receptor (A.Georgakopoulos). ? ? CRITIIQUE: ? ? PRINCIPAL INVESTIGATOR ? ? Dr. Mary Sano, the new Principal Investigator of the Mt. Sinai Center, received her Ph.D. from City University of NY in Neuropsychology. She will replace Dr. Kenneth Davis, who is now the President and CEO of Mt. Sinai. ? ? Dr. Sano has devoted her career to the study of AD, and is a pioneer in the area of clinical trials and development of instrumentation in the area of AD neuropsychology. She has made significant contributions to the field. One of the most notable is the clinical trial of segeline and vitamin E for the treatment of AD, a successful study published in the New England Journal of Medicine. She has been a leader in the development of Spanish speaking instrument protocols, and has continued to collaborate and lead a variety of clinical trials. She is the principal investigator on a primary prevention trial to study effect of estrogen on conversion to dementia. She also leads a multi-center trial on Vitamin E and Down syndrome, and is the PI in the ADCS program to evaluate Simvastatin on the progression of AD. She has excellent organizational skills as evident from her leadership in the Vitamin E study, the organization of the Estrogen, and the Simvastatin trial. She works well with multiple investigators at the same time, and can be relied upon to accomplish her part in a Project in a timely manner. She has a great capacity to poly-task, and manages to meet multiple deadlines at the same time. ? ? Dr. Neil Kowal, who led the external advisory committee in March 2003, shortly after Dr. Sano had taken over the Mt. Sinai ADRC commented it was unanimous opinion of the board that he is exceptionally well suited for the new role as Director. She may have an exemplary record of accomplishment, and the Board is confident in her organizational and administrative skills. ? ? REVIEW OF INDIVIDUAL COMPONENETS ? ? CORE A: ADMINISTRATIVE CORE; Dr. Mary Sano ? ? DESCRIPTION (provided by applicant): The purpose of the Administrative Core of the Alzheimer's Disease Research Center is to maximize the productivity of the Projects and Cores of the Center by the coordination and integration of scientific, fiscal and clerical activities.
The aims of the Core are ? ? To set the research directions of the ADRC. We will commit resources to these themes, including targeted initiatives for pilot Projects To direct the activities of the ADRC. We will continue to use our executive committee to accomplish the goals of the center and we will strengthen/create a structure to accomplish operational and fiscal administration of the grant. ? ? To provide the mechanisms for the review, revision and submission of pilot Projects each year. . ? ? To facilitate ADRC support for AD research that is not directly funded by the ADRC by making the Center's resources available to those studies. ? ? To facilitate interactions among Cores and Projects, as well among other ADCs, and AD based research and service groups. In this renewal we have planned several activities to stimulate interaction between clinical and basic scientist at several local institutions. In addition we have collaborated in several Projects submitted to NACC with other ADCs ? ? To foster the growth of new research and new researchers. The Administrative Core is committed to developing clinician and basic science investigators by providing training, mentoring opportunities and resources in the way of pilot funding to new researchers. ? ? The Core functions through frequent meetings with directors of other Cores and principal investigators of each Project, as well as through a series of internal and external advisory committees that meet regularly. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
3P50AG005138-21A1S1
Application #
7121351
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Phelps, Creighton H
Project Start
1997-05-01
Project End
2010-03-31
Budget Start
2005-09-30
Budget End
2006-03-31
Support Year
21
Fiscal Year
2005
Total Cost
$38,421
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Psychiatry
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Silverman, Jeremy M; Schmeidler, James (2018) Outcome age-based prediction of successful cognitive aging by total cholesterol. Alzheimers Dement 14:952-960

Showing the most recent 10 out of 555 publications